Published on Sun Aug 08 2021

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

Lo, M. K., Shrivastava-Ranjan, P., Chatterjee, P., Flint, M., Beadle, J. R., Valiaeva, N., Schooley, R., Hostetler, K. Y., Montgomery, J., Spiropoulou, C. F.

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524.

3
2
5
Abstract

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.